抗结核药物研究进展  

Progress in the research of anti-tuberculosis drugs

作　　者：王帅[1] 汪静[1] 李清[1] 张惠斌[1] 周金培[1] 

机构地区：[1]中国药科大学药物化学教研室,南京210009

出　　处：《中国新药杂志》2012年第19期2250-2256,2271,共8页Chinese Journal of New Drugs

基　　金：国家自然科学基金资助项目(30973638);江苏省产学研联合创新资金-前瞻性联合研究项目(BY2011158)

摘　　要：肺结核(tuberculosis,TB)是由结核分枝杆菌(mycobacterium tuberculosis,M.tuberculosis)感染引起的,是发展中国家的重大人类疾病之一。人类免疫缺陷病毒(human immunodeficiency virus,HIV)和结核病的双重感染,以及多药耐药(multidrug-resistant,MDR)和广药耐药(extensively drug-resistant,XDR)结核分枝杆菌的出现使得抗结核的形势非常严峻,开发新型抗结核药物已经刻不容缓。鉴于形势如此迫切,研究人员开发了许多具有显著抗结核活性的化合物,其中有一些已经进入临床研究。本文对几类新型抗结核化合物的化学结构、构效关系、抗结核活性以及部分毒理性质进行了综述。Tuberculosis is caused by mycobacterium tuberculosis, which is a haman disease predominantly affecting the developing world. Tuberculosis is often co-infected with human immunodeficiency virus （HIV）. The emergence of muttidrug-resistant （MDR） and extensively drug-resistant （XDR）tuberculosis has made the situation more serious. Thereforel there is an increasing demand for new anti-tuberculosis drugs to effectively control the disease. On the present situation, researchers have increasingly discovered many active candidates with good potential, some of which have entered clinical trials. In this paper, we summarized several new classes of anti-tuberculosis compounds for their structures, structure-activity relationships, activitY and part of toxicity.

关 键 词：肺结核 结核分枝杆菌 多药耐药 抗结核药 

分 类 号：R978.3[医药卫生—药品]